Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy

Qian Cheng1, Jing Pan1, Zhuan-Li Zhou1

  • 1Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, 200032, China.

Acta Pharmacologica Sinica
|September 24, 2020
PubMed

Insights

Pyroptosis, a cell death pathway involving caspase-11/4 and gasdermin D (GSDMD), drives podocyte injury and loss in diabetic nephropathy (DN). Inhibiting this pathway protects against DN development and hyperglycemia-induced damage.

Area of Science:

  • Nephrology
  • Cell Biology
  • Immunology

Background:

  • Diabetic nephropathy (DN) involves sterile inflammation and podocyte injury, crucial for proteinuria.
  • The precise mechanisms of podocyte damage in DN are not fully understood.

Purpose of the Study:

  • To investigate the role of pyroptosis, a programmed cell death pathway, in DN pathogenesis.
  • To determine if caspase-11/4 and gasdermin D (GSDMD) mediate podocyte injury in DN.

Main Methods:

  • Diabetic mouse models induced by high-fat diet/STZ injections.
  • In vitro studies using high glucose to treat cultured human and mouse podocytes.
  • Analysis of pyroptosis markers, podocyte markers, inflammatory cytokines, and kidney pathology.
  • Genetic manipulation using knockout mice and siRNA knockdown.

Main Results:

  • Diabetic mice exhibited elevated caspase-11 and GSDMD-N in podocytes, decreased podocyte markers, foot process effacement, inflammation, and albuminuria.
  • Caspase-11 or GSDMD deficiency ameliorated DN-related changes in mice.
  • High glucose treatment in vitro increased pyroptosis markers and inflammation while decreasing podocyte markers.
  • Caspase-4 or GSDMD knockdown reduced high glucose-induced podocyte damage.

Conclusions:

  • Caspase-11/4 and GSDMD-mediated pyroptosis is activated in podocytes under hyperglycemic conditions.
  • This pyroptosis pathway contributes significantly to podocyte loss and the development of diabetic nephropathy.